Kornimate/medical-research-clean huggingface dataset:
impact of coenzyme q10 and selenium on seminal fluid and semen antioxidant status

Conditions: Male Infertility

Summary: the study was conducted to assess the impact of coenzyme q10 and selenium on seminal fluid parameters and antioxidant status in infertile men.

the aim of this study was to assess the impact of coenzyme q10 and selenium on seminal fluid parameters and antioxidant status in infertile men with idiopathic oligoasthenoteratospermia.

Eligibility criteria:
inclusion criteria: * history of infertility of at least 12 months despite regular unprotected intercourse. * oligoasthenoteratospermia was diagnosed by semen analysis showing abnormal sperm concentration (\<15 million/ml), progressive motility (\<32%), total motility (\<40%) and morphology (\<30% who criteria) as defined by who manual for semen analysis 2010 exclusion criteria: * azoospermia, * varicocele, * genital tract infection, * cryptorchidism, * testicular trauma or scrotal surgery, * endocrine disorder, * systemic illness, * smoking * the presence of female factor

Keywords: male infertility coenzyme q10 selenium antioxidants
prediction of the effect of fluid administration using arterial pressure and ventilator data during abdominal surgery

Conditions: Hypovolemia; Fluid Overload

Summary: it is well known, that patients with circulatory impairment sometimes, but not always, benefit from intravenous fluids. predicting if a fluid administration will improve circulation is therefore of substantial clinical interest. ventilator treatment induces cyclic variation in blood pressure due to interaction between the lungs and the heart. this variation is minor, but its amplitude may be used for guiding fluid administration. however, this method of using ventilator-induced variation in blood pressure to predict the effect of fluid administration was developed when different settings for ventilator treatment was recommended, compared with today. with today's recommend ventilator treatment, the method is, unfortunately, less reliable. the investigators will investigate how different ventilator settings influence variation in blood pressure, and the investigators will test if this knowledge allows us to better predict the effect of a fluid administration, by taking the ventilator settings into account.


Eligibility criteria:
inclusion criteria: * scheduled open abdominal surgery. * scheduled treatment with aarhus university hospital's goal-directed therapy protocol (hemodynamic monitoring). exclusion criteria: * left ventricular ejection fraction ≤ 40 % * irregular heart rhythm (e.g. atrial fibrillation or frequent ectopic beats) * known right ventricular dysfunction (if reported qualitatively in pre-operative assessment or objectively via tricuspid annular plane systolic excursion (tapse) \< 17 mm) * pregnancy * prior participation in this study
virtual reality for youth phobias

Conditions: Specific Phobia; Social Anxiety Disorder; Autism Spectrum Disorder

Summary: the purpose of this study is to examine the effectiveness of virtual reality (vr) delivered exposure therapy for youth with phobias or social anxiety, with and without autism spectrum disorder. the study team is also interested in collecting information to better understand phobias and social anxiety.


Eligibility criteria:
inclusion criteria: 1. the target population for this project are 48 youth (ages of 8-16) that meet criteria for a specific phobia or social anxiety disorder within miami-dade county. 2. youth will be eligible if they or their parent report clinically significant symptoms of social anxiety disorder or a specific phobia targeted with the vr program, based on self- or parent-report scores on online screening measures (\>1 average total scores on severity measure for specific phobia-child or social anxiety disorder-child) or clinician-report diagnosis (i.e., diagnosed with social anxiety disorder or specific phobia during clinical interview). 3. youth are able to complete study procedures, speak/read english or spanish sufficiently. 4. youth have at least one caregiver who can complete all study measures in english or spanish. 5. youth have a caregiver who is available to sign study consent forms, remain present during assessments, and fill out study questionnaires. exclusion criteria: 1. youth who would be inappropriate for a brief vr-exposure therapy protocol will be referred to local resources for additional support or provided with alternate cognitive behavioral therapy services through the clinical center in which this program takes place. 2. research staff will review all measures and the youth's psychological history and consult with the pi to ensure that the participant does not have a current diagnosis of psychosis, bipolar disorder, acute suicidality, alcohol/substance dependence, or eating disorder. 3. youth will also be excluded if they are currently receiving psychotherapy elsewhere. 4. youth with co-occurring intellectual disability may be eligible, but youth who are non-verbal will not be eligible, as some verbal abilities are necessary in order to communicate with the clinician during the intervention. 5. youth who are currently suicidal or who have engaged in suicidal behaviors within the past 6 months will be excluded (or discussed on a case-by-case basis). 6. youth who engage in self-harm behaviors (e.g., cutting) and who do not present with suicidal intent will be allowed to participate. 7. if youth develop psychiatric problems (e.g., severe depression, acute suicidal ideation/intent, severe conduct problems) that require a higher level of care, youth will be withdrawn from the study and referred for appropriate treatment. 8. youth currently taking psychotropic medication for a co-morbid psychiatric illness will be included without a wash-out period (to not delay intervention).

Keywords: virtual reality
bringing advocacy via digital guide to the emergency department (project badge)

Conditions: Diabetes

Summary: the pilot study of project badge will focus on emergency department (ed) patients with diabetes, which has significant disparities in prevalence and mortality for underserved populations. the objective is to determine the effect of a text-based resource referral platform with diabetes educational materials on patient diabetes knowledge, diabetes distress, diabetes self-care activities, and acceptability and feasibility of the intervention.


Eligibility criteria:
inclusion criteria: 1. adult (18+) ed/observation unit patients 2. have poorly controlled or new onset diabetes (hyperglycemia or diabetic ketoacidosis (dka)) 3. speak english or spanish 4. has a cell phone able to send and receive text messages exclusion criteria: 1) intubated patient
serial changes after drug-coated balloon

Conditions: Coronary Artery Disease

Summary: the study aims at evaluating the morphological changes of plaque estimated by optical coherence tomography (oct) and factors influencing plaque healing after drug-coated balloon (dcb) for de novo coronary lesions.

percutaneous coronary intervention with a drug-eluting stent (des) is the most common mode of revascularization for coronary artery disease. however, their efficacy is limited by in-stent restenosis and stent thrombosis. drug-coated balloon (dcb) deliver an anti-proliferative drug into the vessel wall and leave nothing behind, which is a promising technique in the treatment of coronary artery disease. previous many studies have confirmed that dcb treatment for de novo coronary lesions is safe and efficient. but, data about morphological changes of plaque and factors influencing plaque healing after dcb for de novo coronary lesions is scarce. the study compares morphological changes of plaques evaluated by oct between baseline and 1-year follow-up and evaluates factors influencing plaque healing. all the included patient will receive dual antiplatelet therapy (dapt) for one month followed by clopidogrel treatment.

Eligibility criteria:
inclusion criteria: - diagnosed as cad underwent coronary angiography and oct examination. * patients with de novo lesion suitable for dcb treatment. * the reference diameter of targeted artery ≥2.75mm, the length of targeted lesion ≤25mm. * agreed to accept dcb treatment and written the informed consent. exclusion criteria: * patients with de novo lesion unsuitable for dcb treatment. * in-stent restenosis, coronary dissection, coronary spam, thrombus * left main artery disease * age\>80 years old * cardiogenic shock or stroke admission * severe hepatic or renal dysfunction * poor quality of oct image or massive thrombus * disagreed to accept dcb treatment. * life expectancy \< 1year. angiographic exclusion criteria * after pre-dilation of targeted lesions, the patients with residual stenosis\>30%, timi flow \<iii grade and presence of major dissection (c type or higher).
analysis of immunological reactions to foods in birch pollen-allergic patients

Conditions: Allergic Rhinitis; Food Allergy

Summary: a high number of birch pollen-allergic individuals develop hypersensitivity reactions to certain foods, e.g. apples. this food allergy is due to immunological cross-reactivity. birch pollen-related foods contain proteins, e.g. mal d 1 in apple, that are structurally related with the major birch pollen allergen, bet v 1. hence ige antibodies and t lymphocytes specific for bet v 1 recognize these food proteins which results in activation of the immune system and, consequently, in clinical symptoms. in the present study the investigators intend to investigate if and how the consumption of birch pollen-related food allergens affects birch pollen allergy. in other words, the investigators are interested to analyse whether bet v 1-related food allergens activate bet v 1-specific memory cells and thus, contribute to the maintenance of the pollen allergy outside the pollen season. data obtained in this study will help to clarify the immunological and clinical role of cross-reactivity between pollen and food allergies and will reveal whether avoidance of such foods should be recommended for the patients. finally, novel approaches for diagnosis and therapy of pollen-related food allergens can be developed.


Eligibility criteria:
inclusion criteria: * otherwise healthy birch pollen allergic (rhinoconjunctivitis)persons * positive spt and rast to birch pollen * sensitized to bet v 1 exclusion criteria: * persons suffering from malignancies, autoimmune and cardiopulmonary diseases * anemia * hyper-ige syndrome * treatment with ß-blockers, permanent treatment with antihistaminics, leucotriene antagonists, corticosteroids

Keywords: birch pollen pollen allergy oral allergy syndrome to apple cross reactivity bet v 1 mal d 1
midterm (min. 3yr) follow-up of patients with single spiral/oblique finger metacarpal fracture

Conditions: Metacarpal Fracture

Summary: spiral metacarpal fractures (metacarpal ii-v) can be treated conservatively or with operation. with minimal displacement this fracture is usually treated with immobilisation or early mobilisation. with appreciable displacement especially any malrotation the patient usually is treated with an operation. this usually includes an open reduction of the fracture and fixation with plates and screws or just screws. the hypothesis that nonoperative treatment (using early mobilization without splintage) will result in similar outcomes to operative treatment was previously tested by this research group (peyronson et al. jbjs american 2023). over a 1-year follow-up the primary outcome of grip strength was found to be noninferior. this trial will extend the follow-up period and re-evaluate the patients included in the original cohort to identify any difference over a 3-6 year follow up.

the original trial was a noninferiority randomized controlled trial evaluating 42 patients. randomization was performed 1:1 to either nonoperative treatment with mobilization initiated immediately following recruitment or operative treatment using orif with cortical screws or locking compression plate (lcp) and screw fixation. the non-inferiority margin (nim) was defined as -15% grip strength of the injured hand relative to the contralateral hand. the same nim will be used for this trial. because subtle biomechanical changes (mainly metacarpal bone shortening) could theoretically cause problems not evident at 1-year follow-up (such as joint degeneration from changes in load distribution), the investigators plan to re-evaluate the patients for a longer-term follow-up. only patients included in the original trial will be eligible for inclusion in this extended follow-up. participation will be offered via mail invitation, and participants will be offered financial compensation in the form of a single payment of 500sek. data collection will be performed in a single outpatient hospital visit where patient history, subjective outcome data and bilateral plain radiography of the hands will be obtained.

Eligibility criteria:
inclusion criteria: previous inclusion in the original study population, i.e.: * diaphyseal, single spiral, and oblique fractures of the index to little finger metacarpals * fracture line length at least twice the diameter of the bone at the level of the fracture * at least 2-mm displacement and/or shortening of the fracture or malrotation * normal hand function before the injury * fracture \<10 days old exclusion criteria: * multiple metacarpal fractures * open fractures * inability to follow instructions * fracture line length less than twice the diameter of the bone at the level of the fracture * abnormal hand function before the injury * previous ipsilateral hand fractures * fracture ≥10 days old at possible randomization

Keywords: metacarpal fracture spiral fracture early mobilization
the investigation of mechanical properties in obesity.

Conditions: Body Fat Disorder; Obesity; Muscular Tone; Viscoelasticity

Summary: the study will demonstrate the relation between muscle tone and viscoelastic properties with the body mass index.

obesity is an increasingly important health problem. it can be defined as excessive fat accumulation. obesity is a low-severity systemic inflammatory condition that predisposes to chronic diseases.obesity is closely related to adipose tissue, it can have direct or indirect effects on physical activity and musculoskeletal system. the systems working with oscillation techniques, subcutaneous tissue thickness may affect the probe stroke of the device and oscillation in the tissue. in previous studies were investigated mechanical properties, and bmi used as exclusion criteria is over 30 kg/meter square or keeping it at certain intervals (18-28 kg /meter square) but this proof is not demonstrated and still lack.this study is planned to determine the relation of mechanical properties (tone, stiffness and elasticity) obtained by myotonometric assessment with body mass index.

Eligibility criteria:
inclusion criteria: * body mass index (range; 18 - 35 kg/meter square) exclusion criteria: * had any systemic or metabolic disease, psychological illness, or drug use, * had any disease that may cause muscle disease or muscle atrophy, * musculoskeletal surgery for the last 3 months

Keywords: body mass index tone viscoelasticity obesity
impact of aerobic exercise in addition to nutritional treatment on quality of life after pancreatectomy

Conditions: Pancreatic Tumors; Diabetes; Malabsorption

Summary: the goal of this interventional study is to assess the impact of a 6-month unsupervised aerobic exercise program on the quality of life of patients undergoing partial or total pancreatectomy. the main question it aims to answer is: does an aerobic exercise program improve physical functioning and overall quality of life in post-pancreatectomy patients? eligible participants will be assigned to either an exercise group or a control group. quality of life will be evaluated using standardized scoring scales, with a focus on physical functioning. secondary outcomes include changes in metabolic parameters (glycemia, hba1c, lipid profile), bmi, and overall survival.


Eligibility criteria:
inclusion criteria: * signed informed consent * male or female patients who have undergone partial or total pancreatectomy * age ≥18 and ≤80 years * ability to understand and complete questionnaires and willingness to participate in periodic assessments * no symptoms suggestive of cardiovascular issues (e.g., angina, dyspnea, palpitations, syncope) * no evidence of ischemic heart disease, cardiomyopathy, valvular heart disease, myocarditis, autoimmune diseases, infections, or fractures that would contraindicate moderate-intensity aerobic activity exclusion criteria: * age \>80 or \<18 years * cardiovascular, musculoskeletal, rheumatologic, or neurocognitive disorders contraindicating aerobic exercise * 10-year cardiovascular risk \>20% without cardiological/sports medicine evaluation * diagnosis of unresectable tumor * presence of metastases * pregnancy or breastfeeding * ongoing chemotherapy and/or radiotherapy * bmi ≥30 * bmi ≤18.5

Keywords: pancreatectomy quality of life physical exercise
mifamurtide (l-mtp-pe) for high-risk osteosarcoma

Conditions: Osteosarcoma

Summary: the purpose of this study was to collect information regarding the safety and tolerability of mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; l-mtp-pe).

the drug being tested in this study is called mifamurtide (l-mtp-pe; liposomal muramyl tripeptide phosphatidyl ethanolamine). mifamurtide is being used to treat people with osteosarcoma, a form of cancer. this was a patient-access study that looked at adverse events, disease progression, and overall survival in study participants. the study enrolled 205 patients, of whom 204 were treated with mifamurtide intravenously at a dose of 2 mg/m2 twice weekly (at least 3 days apart) for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks (following surgery for primary or metastatic disease). this study was conducted in the united states. participants could receive treatment for up to 9 months. this study was previously mis-categorized as an interventional study.

Eligibility criteria:
inclusion criteria: 1. had signed informed consent/assent. voluntary participation in the pharmacokinetic portion of the compassionate access protocol was included in the informed consent but not required for compassionate use participation. 2. had diagnosis of high grade osteosarcoma with relapsed or recurrent disease, locally or metastatic, with disease not completely resectable or who were unable to complete recommended chemotherapy due to toxicity: relapse, recurrence local or metastatic; unable to have standard surgical resection; abbreviated chemotherapy regimen secondary to toxicity (e.g. hypophosphatemia from ifosfamide, cardiotoxicity from doxorubicin, renal dysfunction from methotrexate, ifosfamide, or cisplatin.) 3. aged 2 ≤ 50 years. 4. had adequate hematopoietic function as demonstrated by: 1) absolute neutrophil count (anc) \> 750/microl; hemoglobin (hb) \> 8 g/dl; platelets \> 30,000/microl. 5. had adequate hepatic function as documented by 1) alt \< 2.5 x upper limit of normal (uln) for age; 2) total bilirubin ≤ 1.5 x uln for age. 6. had adequate renal function as demonstrated by: 1) creatinine clearance or radioisotope glomerular filtration rate \> 70 ml/min/1.73 m\^2; or, 2) serum creatinine ≤ 2x uln for age. 7. had absence of concurrent active acute infection (i.e., afebrile). 8. in females of child bearing potential (not menopausal for 12 months or no previous surgical sterilization), had a negative pregnancy test. all sexually active participants used an effective means of contraception. such means included oral contraceptives, lupron depot, depoprovera, and condom with diaphragm and spermicidal jelly. 9. performance status: lansky 50-100% (≤ 16 years of age); or, eastern cooperative oncology group (ecog) 0-2 or karnofsky 50-100% (\>16 years of age). exclusion criteria: 1. had chronic use of corticosteroids or other immunosuppressive agents. 2. was pregnant or breast-feeding.

Keywords: drug therapy
a clinical study for validating the equivalence of bloomlife mfm-pro to clinical standard-of-care for performing antepartum fetal monitoring

Conditions: Fetal Monitoring

Summary: bloomlife mfm-pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy, starting from 32 weeks of gestation. the purpose of this study is to validate that the bloomlife mfm-pro is equivalent to clinical standard-of-care for fetal heart rate and maternal heart rate when performing antepartum fetal monitoring.

the study consisted of 2 phases: a pilot phase and a pivotal phase. the pilot phase of the study was aimed at testing the bloomlife mfm-pro device prior to validation in the pivotal phase of the study. the pivotal phase of the study was aimed at validating that the bloomlife mfm-pro is equivalent to clinical standard-of-care for fetal heart rate and maternal heart rate when performing antepartum fetal monitoring.

Eligibility criteria:
inclusion criteria: * pregnant woman ≥ 18 years old * gestational age ≥ 32 weeks and 0 days * singleton pregnancy * ability to read and understand english or spanish * willingness to participate in the study exclusion criteria: * implanted pacemaker or any other implanted electrical device * plurality higher than 1 * history of allergies to skin adhesives * irritated or lesioned skin at the bloomlife mfm-pro electrodes locations * contraindication to the use of ctg
diagnostic accuracy of multislice ct angiography for acute chest pain

Conditions: Chest Pain; Acute Coronary Syndrome; Pulmonary Embolism; Aortic Dissection

Summary: the acute ct trial is designed to test whether the assessment of chest structures by high-resolution multislice computed tomography (ct) provides equivalent diagnostic accuracy for patient with acute chest pain or other potential cardiac symptoms as compared to a standard of care evaluation.

adults at low to intermediate risk of acute coronary syndrome who present to the emergency department with symptoms suggestive of cardiac ischemia will undergo a blinded cardiac ct followed by a standard of care (soc) strategy. significant coronary artery disease on ct (coronary stenosis \>50%) will be compared to an adjudicated diagnosis derived from clinical data and other diagnostic tests based on the soc strategy. costs for the soc evaluation will be collected and compared to a ct-based evaluation. patients will be followed for 3 years after enrollment to evaluate prognosis.

Eligibility criteria:
inclusion criteria: * low to intermediate risk of angina with a timi acs risk score ≤ 4 * chest pain or other symptoms suggestive of acs within 24 hours * male ≥30 years or female ≥45 years old * at least one cardiac risk factor * no obvious cause for symptoms. exclusion criteria: * known cad * st segment elevation, new left bundle branch block or dynamic ecg changes * creatinine ≥1.8 g/dl * pregnant or lactating female * hemodynamic or respiratory instability * ongoing bronchospasm * known iodinated contrast allergy * atrial fibrillation or irregular heart rate

Keywords: acute coronary syndrome coronary artery disease cardiac imaging computed tomography